Thursday, September 18, 2025

Latest

Cytophage Develops Freeze-Dried Phage Tablets For Poultry

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies.

Cytophage Technologies (TSXV: CYTO) has announced the launch of a simplified application option for its bacteriophages that it believes will set itself apart within the phage industry globally.

The company has developed a lyophilized phage tablet intended to treat multiple types of bacteria, including E. coli and Salmonella, throughout the lifecycle of poultry. The use of lyophilized phage tablets is providing an alternative to the liquid form that is presently used in the industry, which most often requires a cold chain.

”The importance of eliminating the need for a cold chain cannot be overstated. Offering phages in lyophilized form represents a competitive advantage over other phage producers who have only liquid products that require refrigeration. Our innovative manufacturing increases our products’ heat tolerance and shelf-life,” commented Dr Steven Theriault.

READ: Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

The tablets are freeze dried and stabilized, which enable Cytophage’s phage products to be more easily used in hot climates such as Southeast Asia. The tablets are ready to use, dose controlled, and dissolve in water for application.

Development of the tablet is said to be a direct response to Cytophage working with the poultry industry on phage products that assist in reducing the use of broad-spectrum antibiotics, and replacing those antibiotics with target phages. The firm intends to leverage the new product format across its existing and pending product lines globally.

Cytophage Technologies last traded at $0.35 on the TSX Venture.


FULL DISCLOSURE: Cytophage Technologies is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cytophage Technologies. The author has been compensated to cover Cytophage Technologies on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why $10K Gold No Longer Sounds Crazy | Dan Wilton – First Mining Gold

The Pure Silver Set Up! | Joaquin Marias – Argenta Silver Corp

Why $30,000 Gold Isn’t Crazy! | Simon Marcotte – Northern Superior

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Cytophage Enters Partnership To Launch Phage Clinical Treatment Program In Manitoba

Cytophage Technologies (TSXV: CYTO) announced a landmark agreement this morning that will see the establishment...
Thursday, December 12, 2024, 05:14:00 PM

Cytophage Enters Letter Of Intent With Major Singapore-Based Agrifood Company

Cytophage Technologies (TSXV: CYTO) is focusing its efforts on expanding the commercialization of its phage...
Friday, June 21, 2024, 08:45:08 AM

Phage Therapy’s Rising Demand: Cytophage at the Forefront with Dr. Steven Theriault

In this interview, Dr. Steven Theriault, CEO of Cytophage Technologies Ltd. (TSXV:CYTO), presents phage therapy...
Thursday, August 15, 2024, 02:04:00 PM

The Solution To Antibiotic Resistance – With Cytophage CEO Dr Steven Theriault

FULL DISCLOSURE: This is sponsored content for Cytophage Technologies. In this interview, Dr. Steven Theriault...

Thursday, February 22, 2024, 01:30:00 PM

Cytophage To Focus On Commercialization Efforts In 2024

Cytophage Technologies (TSXV: CYTO) has filed its fiscal 2023 results, providing a recap on a...
Tuesday, April 30, 2024, 10:13:02 AM